HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.310

-0.070-0.67%

Volume:4.54M

Turnover:46.60M

Market Cap:4.20B

PE:-11.63

High:10.440

Open:10.440

Low:10.120

Close:10.380

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.52

T/O Rate:1.46%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-62.88%

ROA:-32.06%

PB:8.64

PE(LYR):-11.63

PS:- -

Loading ...

Overview Company News Filings

TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t

Bulletin Express

Transthera Sciences publishes 2025 annual report

TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%

Bulletin Express

TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net

Transthera files HKEX return on 5,085,000 H-share issue at HKD 57.03

TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each

TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR

TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026

Bulletin Express

TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting

TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial

MT Newswires Live

TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma

TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma

TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount

TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount

Bulletin Express

TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each

Transthera Sciences (Nanjing) Inc - Placing of 5.1 Mln Shares at HK$57.03 per Share

THOMSON REUTERS

TRANSTHERA-B Proposes Implementation of H-Share Incentive Scheme

TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod

Bulletin Express

TransThera proposes H-share award scheme for employee compensation

TransThera Sciences files directors list with Hong Kong Stock Exchange

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02617/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.31,"timestamp":1787299687057,"preClose":10.38,"halted":0,"volume":4543800,"delay":0,"changeRate":-0.006743737957610817,"floatShares":312000000,"shares":407000000,"eps":-0.8866696460072915,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"08-21 16:08:07","open":10.44,"high":10.44,"low":10.12,"amount":46601191,"amplitude":0.030829,"askPrice":10.31,"askSize":5000,"bidPrice":10.3,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.8861493109255556,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.38,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5223118835745755,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.88667,"volumeRatio":0.5223118835745755,"shares":407000000,"dividePrice":0,"high":10.44,"amplitude":0.030829,"preClose":10.38,"low":10.12,"week52Low":9.01,"pbRate":"8.64","week52High":679.5,"institutionHeld":0,"latestPrice":10.31,"committee":0.354839,"eps":-0.8866696460072915,"divideRate":0,"volume":4543800,"delay":0,"ttmEps":-0.8861493109255556,"open":10.44,"prevYearClose":114.9,"prevWeekClose":10.31,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.33,"twentyDayClose":10.19,"sixtyDayClose":38.7,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-21","current":-11.632445,"percent":0.95122,"low":-380.446233,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"high":-10.87103,"avg":-114.757849,"sd":96.187407,"marketCap":4205641106},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106}],"updateTime":1787493137953},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113824509","title":"TransThera unveils inaugural ESG report: Tinengotinib NDA accepted, 2025 greenhouse-gas emissions at 728.89 t","url":"https://stock-news.laohu8.com/highlight/detail?id=1113824509","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113824509?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:47","pubTimestamp":1776955626,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. released its first Environmental, Social and Governance Report, covering operations from 1 January to 31 December 2025 and focusing on headquarters, R&D centre and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629725858","title":"Transthera Sciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629725858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629725858?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:33","pubTimestamp":1776954802,"startTime":"0","endTime":"0","summary":"Global expansion remained central, supported by a registrational Phase III multi-regional trial for Tinengotinib across U.S., EU, U.K., South Korea, Taiwan; enrollment expected to complete in 2026.Pipeline breadth increased, with six clinical-stage candidates spanning oncology, inflammatory, cardiometabolic diseases; Tinengotinib programs advanced in prostate cancer, breast cancer, liver cancer.Business development accelerated via November 2025 NLRP3 collaboration with Neurocrine Biosciences, carrying potential total value up to USD 881.5 million.Management outlook targeted China NDA approval in 2026 for Tinengotinib, with commercialization team buildout planned for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Scienc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL1LmypC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0154245673.USD","LU0109394709.USD","LU2065169927.USD","NBIX","LU2324357040.USD","LU0823416689.USD","BK1161","LU0154245756.USD","02617","LU2065171402.SGD","LU2065170008.USD","LU2065171311.SGD","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106715629","title":"TransThera Completes HK$290.00 Million H-Share Placement at HK$57.03 Each, Expanding Free Float by 1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106715629","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106715629?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:23","pubTimestamp":1776770596,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. announced the successful completion of its new H-share placement on 21 April 2026. A total of 5.09 million H shares were placed with no fewer than six professional...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112729517","title":"TRANSTHERA-B Completes Placement of 5.085 Million Shares, Raising Approximately HK$282 Million Net","url":"https://stock-news.laohu8.com/highlight/detail?id=1112729517","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112729517?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:08","pubTimestamp":1776769703,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced the fulfillment of all conditions under the placement agreement, with the placement completed on April 21, 2026. The placing agent successfully allocated a total of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033567","title":"Transthera files HKEX return on 5,085,000 H-share issue at HKD 57.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033567","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033567?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:06","pubTimestamp":1776769609,"startTime":"0","endTime":"0","summary":"TransThera Sciences filed a next day disclosure return reporting issuance of 5,085,000 new H shares on April 21, 2026.Issued shares outstanding rose to 308,851,673 from 303,766,673.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLdzmHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629333070","title":"TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2629333070","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629333070?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769486,"startTime":"0","endTime":"0","summary":"TransThera Sciences completed private placement of 5,085,000 new H shares at HK$ 57.03 each on April 21, 2026.Gross proceeds totaled about HK$ 290 million; net proceeds were about HK$ 282.2 million.Funds earmarked mainly for R&D and clinical development of Tinengotinib, with additional allocation toward manufacturing and commercialization in China.Total issued shares rose to 404,082,633 from 398,997,633 following issue of placing shares.Placees bought about 1.3% of enlarged share capital; none became substantial shareholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Excha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL48jwCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121493501","title":"TRANSTHERA-B (02617) Presents Lineage Plasticity as Resistance Mechanism in HR+ Breast Cancer Endocrine Therapy and Preclinical Data for Tiengotinib at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1121493501","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121493501?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:10","pubTimestamp":1776730218,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the company presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The poster disclosed lineage plasticity as a driver...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HR","BK4225","02617","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184291572","title":"TransThera Highlights FGFR-JAK–Mediated Resistance in HR+ Breast Cancer and Showcases Tinengotinib Preclinical Efficacy at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1184291572","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184291572?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:02","pubTimestamp":1776729777,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) released new translational and preclinical findings at the 2026 American Association for Cancer Research (AACR) Annual Meeting, identifying lineage...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041772","title":"TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041772?lang=en_us&edition=fundamental","pubTime":"2026-04-21 08:00","pubTimestamp":1776729643,"startTime":"0","endTime":"0","summary":"TransThera Sciences will present a poster at AACR Annual Meeting on April 20, 2026, 9:00 AM–12:00 PM PDT.Presentation will cover endocrine therapy resistance in HR+ breast cancer, citing convergent FGFR-JAK signaling as a driver of lineage reprogramming.Poster will also show preclinical data indicating tinengotinib restored luminal identity, resensitizing resistant models to endocrine therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL3vdWMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278208","title":"TransThera Sciences Doses First Patient in Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278208","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278208?lang=en_us&edition=fundamental","pubTime":"2026-04-17 19:10","pubTimestamp":1776424232,"startTime":"0","endTime":"0","summary":"TransThera Sciences   dosed the first patient in a confirmatory phase III clinical trial of Tinengotinib, according to a Friday Hong Kong bourse filing.The drug is being tested as a monotherapy for the treatment of patients with advanced cholangiocarcinoma, the clinical-stage biopharmaceutical firm said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176775881","title":"TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1176775881","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176775881?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:44","pubTimestamp":1776422683,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628270114","title":"TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2628270114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628270114?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:40","pubTimestamp":1776422454,"startTime":"0","endTime":"0","summary":"TransThera dosed first patient in China confirmatory Phase III trial of tinengotinib monotherapy for advanced intrahepatic cholangiocarcinoma with FGFR2 alterations.Study will compare tinengotinib versus chemotherapy in patients whose disease relapsed or progressed following first-line systemic therapy.No clinical results were presented; efficacy and safety readout will be generated in future as trial progresses.Program supports marketing push in China, with tinengotinib already at NDA review stage following completion of pivotal Phase II study.Company positioned drug as potential option for patients previously treated with FGFR inhibitors, targeting unmet need tied to treatment resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL57VbVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121459065","title":"TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1121459065","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121459065?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:06","pubTimestamp":1776207983,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has entered into a placement agreement with a placement agent. The agreement, dated April 14, 2026, stipulates that the agent will use its best efforts to place 5.085 million...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178263361","title":"TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1178263361","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178263361?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:43","pubTimestamp":1776206599,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (abbreviated “TransThera Sciences”) on 14 April 2026 signed a conditional placing agreement with Macquarie Capital Limited to issue 5.09 million new H shares at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291427","title":"TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291427","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291427?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:32","pubTimestamp":1776205929,"startTime":"0","endTime":"0","summary":"TransThera Sciences entered a placing agreement to sell 5,085,000 new H shares at HK$ 57.03 each.Deal size implies gross proceeds of about HK$ 290 million.Pricing represents an 18% discount to April 14 close of HK$ 69.55.Net proceeds expected at about HK$ 282.2 million.Funds earmarked mainly for R&D and Tinengotinib manufacturing and commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3kD9vl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542725","title":"Transthera Sciences (Nanjing) Inc -  Placing of 5.1 Mln Shares at HK$57.03 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542725","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542725?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:31","pubTimestamp":1776205891,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190520691","title":"TRANSTHERA-B Proposes Implementation of H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1190520691","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190520691?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:44","pubTimestamp":1775565852,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that its board of directors passed a resolution during a meeting held on April 7, 2026, recommending the adoption of an H-share incentive plan. The awards under the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148728314","title":"TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=1148728314","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148728314?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:45","pubTimestamp":1775562327,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937130","title":"TransThera proposes H-share award scheme for employee compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937130?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:40","pubTimestamp":1775562013,"startTime":"0","endTime":"0","summary":"Transthera Sciences board on April 7, 2026 proposed adoption of a 2026 H share award scheme.Awards would be settled using treasury shares, newly issued H shares, or existing H shares.Plan defines awards as share options or share awards granted to eligible participants.Company plans to call an extraordinary general meeting to seek shareholder backing for scheme adoption.Scheme would also require listing approval for shares to be issued under awards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 07, 2026, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLcgT3vd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593585","title":"TransThera Sciences files directors list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593585?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:26","pubTimestamp":1774995960,"startTime":"0","endTime":"0","summary":"Transthera Sciences  filed list of directors and board committee roles with Hong Kong Stock Exchange dated March 31, 2026.Board includes two executive directors: Frank Wu, Wu Di.Independent non-executive directors include Chui Hoi Yam, Zheng Zhelan, Li Shu Pai.Committee leadership includes Li Shu Pai chairing Audit Committee, Zheng Zhelan chairing Remuneration and Appraisal Committee, Chui Hoi Yam chairing Nomination Committee, Frank Wu chairing Strategy Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLFz9hZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0081","BK0082","BK1161","BK0102","BK0215","600962","02617","BK0010"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":140,"code":"91000000","status":"200"}]}}